Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
French biotech company Abivax strongly rejects media claims that it gave AstraZeneca secret access to its data for a possible buyout until March 23, calling the reports "unfounded rumors."
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.